Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, join a growing list of provinces providing public drug plan reimbursement for Teva Canada's AJOVY® (fremanezumab), for the preventive treatment of migraine in adults
Ticker Tech,
Public formulary and program coverage makes AJOVY® accessible to more migraine patients across Canada MONTRÉAL, May 17, 2022 /CNW…